Insuman Comb 50 (Insulin Human)

Insulin human mimics the action of naturally produced insulin by binding to insulin receptors on muscle, fat and liver cells. This triggers intracellular pathways that increase glucose uptake, promote glycogen synthesis, and suppress hepatic glucose output, thereby lowering circulating blood glucose concentrations.

The dose of Insuman Comb 50 is individualized and determined by the prescribing healthcare professional based on the patient’s blood glucose readings, carbohydrate intake, activity level and overall treatment goals. Patients should follow the dosing instructions provided by their prescriber.

Insulin is generally considered the preferred glucose‑lowering therapy during pregnancy because it does not cross the placenta in significant amounts. Insuman Comb 50 may be used when the expected benefit outweighs any potential risk. Breastfeeding mothers should consult their physician, as insulin is present in very low concentrations in breast milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and required import documentation.

Insuman Comb 50 contains human insulin, which is structurally identical to endogenous insulin, whereas many newer insulin analogues have modified amino‑acid sequences to alter onset and duration. Human insulin offers a well‑established safety profile and is often more cost‑effective, but analogues may provide more flexible dosing schedules for some patients.

Insuman Comb 50 should be stored in a refrigerator at 2‑8 °C (36‑46 °F). Keep the vial in its original packaging, protect it from light, and avoid freezing. Once in use, the product may be kept at controlled room temperature (up to 30 °C) for a maximum of 28 days, after which any remaining insulin should be discarded.

Insuman Comb 50 is administered by subcutaneous injection into the abdomen, thigh or upper arm. The injection technique, rotation of sites and timing relative to meals should follow the prescribing clinician’s instructions. Patients should be trained on proper needle handling, injection depth and disposal of sharps.

The most serious risks include severe hypoglycemia, which can lead to loss of consciousness or seizures, and rare allergic reactions such as anaphylaxis. Patients should be educated to recognize early signs of hypoglycemia, monitor blood glucose regularly, and seek immediate medical attention if they experience any signs of a severe allergic response.

Insuman Comb 50 is contraindicated in individuals with a known hypersensitivity to human insulin or any of the product’s excipients. It should also be avoided in patients experiencing hypoglycemia until the condition is resolved. Clinicians must assess each patient’s medical history before initiating therapy.